(2020) (69) performed a prospective real-world analysis of 268 patients with advanced NSCLC treated with anti-PD-1 monotherapy (IO) at the Princess Margaret Cancer Center and used logistic regression to test factors associated with response to treatment, including PD-L1 tumor proportion score (TPS) and smoking status. The gene discussed is CD274; the disease is neoplasm.